Figure 1From: Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) Kaplan-Meier survival estimate. c.35 G > A KRAS mutant patients versus KRAS wild-type patients. 1, progression-free survival; 2, overall survival.Back to article page